238 related articles for article (PubMed ID: 22342124)
61. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
[TBL] [Abstract][Full Text] [Related]
62. Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable.
Buttar D; Edge M; Emery SC; Fitzek M; Forder C; Griffen A; Hayter B; Hayward CF; Hopcroft PJ; Luke RW; Page K; Stawpert J; Wright A
Bioorg Med Chem Lett; 2008 Aug; 18(16):4723-6. PubMed ID: 18676144
[TBL] [Abstract][Full Text] [Related]
63. Synthesis of novel pyrazolo[3,4-d]pyrimidine derivatives as potential anti-breast cancer agents.
Abd El Hamid MK; Mihovilovic MD; El-Nassan HB
Eur J Med Chem; 2012 Nov; 57():323-8. PubMed ID: 23085106
[TBL] [Abstract][Full Text] [Related]
64. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.
Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG
Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066
[TBL] [Abstract][Full Text] [Related]
65. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
66. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
[TBL] [Abstract][Full Text] [Related]
67. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
[TBL] [Abstract][Full Text] [Related]
68. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities.
Lücking U; Siemeister G; Schäfer M; Briem H; Krüger M; Lienau P; Jautelat R
ChemMedChem; 2007 Jan; 2(1):63-77. PubMed ID: 17131463
[TBL] [Abstract][Full Text] [Related]
69. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
70. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.
Manetti F; Brullo C; Magnani M; Mosci F; Chelli B; Crespan E; Schenone S; Naldini A; Bruno O; Trincavelli ML; Maga G; Carraro F; Martini C; Bondavalli F; Botta M
J Med Chem; 2008 Mar; 51(5):1252-9. PubMed ID: 18257513
[TBL] [Abstract][Full Text] [Related]
71. Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.
Liu JJ; Daniewski I; Ding Q; Higgins B; Ju G; Kolinsky K; Konzelmann F; Lukacs C; Pizzolato G; Rossman P; Swain A; Thakkar K; Wei CC; Miklowski D; Yang H; Yin X; Wovkulich PM
Bioorg Med Chem Lett; 2010 Oct; 20(20):5984-7. PubMed ID: 20832307
[TBL] [Abstract][Full Text] [Related]
72. Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Arcari JT; Beebe JS; Berliner MA; Bernardo V; Boehm M; Borzillo GV; Clark T; Cohen BD; Connell RD; Frost HN; Gordon DA; Hungerford WM; Kakar SM; Kanter A; Keene NF; Knauth EA; Lagreca SD; Lu Y; Martinez-Alsina L; Marx MA; Morris J; Patel NC; Savage D; Soderstrom CI; Thompson C; Tkalcevic G; Tom NJ; Vajdos FF; Valentine JJ; Vincent PW; Wessel MD; Chen JM
Bioorg Med Chem Lett; 2013 May; 23(10):3059-63. PubMed ID: 23566514
[TBL] [Abstract][Full Text] [Related]
73. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent.
Curran KJ; Verheijen JC; Kaplan J; Richard DJ; Toral-Barza L; Hollander I; Lucas J; Ayral-Kaloustian S; Yu K; Zask A
Bioorg Med Chem Lett; 2010 Feb; 20(4):1440-4. PubMed ID: 20089401
[TBL] [Abstract][Full Text] [Related]
74. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
75. 3,5-diarylazoles as novel and selective inhibitors of protein kinase D.
Gamber GG; Meredith E; Zhu Q; Yan W; Rao C; Capparelli M; Burgis R; Enyedy I; Zhang JH; Soldermann N; Beattie K; Rozhitskaya O; Koch KA; Pagratis N; Hosagrahara V; Vega RB; McKinsey TA; Monovich L
Bioorg Med Chem Lett; 2011 Mar; 21(5):1447-51. PubMed ID: 21300545
[TBL] [Abstract][Full Text] [Related]
76. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
78. Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region.
Gopalsamy A; Yang H; Ellingboe JW; Tsou HR; Zhang N; Honores E; Powell D; Miranda M; McGinnis JP; Rabindran SK
Bioorg Med Chem Lett; 2005 Mar; 15(6):1591-4. PubMed ID: 15745803
[TBL] [Abstract][Full Text] [Related]
79. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors.
Su Q; Ioannidis S; Chuaqui C; Almeida L; Alimzhanov M; Bebernitz G; Bell K; Block M; Howard T; Huang S; Huszar D; Read JA; Rivard Costa C; Shi J; Su M; Ye M; Zinda M
J Med Chem; 2014 Jan; 57(1):144-58. PubMed ID: 24359159
[TBL] [Abstract][Full Text] [Related]
80. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
